Apply for Grants
Explore funding opportunities that drive innovation in cancer immunotherapy
The Cancer Research Institute (CRI) offers competitive research grants, fellowships, and awards to support scientists at every stage of their careers. Whether you’re an early-career investigator or an established researcher, CRI’s grant programs are designed to advance groundbreaking discoveries and accelerate the development of life-saving immunotherapies. Learn how to apply and join our global network of immuno-oncology pioneers.
CRI Irvington Postdoctoral Fellowship
Career development and support for laboratory research for promising young immunologists
Application Deadline
March 1; September 1
CRI Irvington Postdoctoral Fellowship to Promote Racial Diversity
Career development and support for laboratory research for underrepresented scientists in immuno-oncology
Application Deadline
March 1; September 1
CRI Immuno-Informatics Postdoctoral Fellowship
Support for qualified young scientists who wish to receive dual training in immunology and data science
Application Deadline
March 1; September 1
Clinic and Laboratory Integration Program (CLIP)
Translating of basic laboratory discoveries into novel therapies
LOI Deadline
December 1
Total Funding
$300,000
Technology Impact Award
Addressing the gap between technology development and clinical application of cancer immunotherapies
LOI Deadline
November 15
Total Funding
$300,000
Lloyd J. Old STAR Program
Mid-career support for the future “stars” in cancer immunology
Application Deadline
January 15
Total Funding
$1.25M
Clinical Innovator
Support for innovative immunotherapy clinical trials
Protocol Concept Deadline
December 1
Total Funding
$1M
CRI Awards & Honors
CRI recognizes research pioneers that drive major advances in immunology and cancer immunotherapy.
CRI Funded Scientists
These current and future scientific leaders in immunology and tumor immunology, from top academic research institutions, are advancing fundamental and applied discoveries that impact cancer research. From bench to bedside, CRI is ushering in the next generation of cancer immunotherapy innovations.